Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy. Issue 4 (5th April 2022)

• Record Type: Journal Article
• Authors: Sato, Ken; Yamazaki, Yuichi; Kanayama, Yuki; Uehara, Daisuke; Tojima, Hiroki; Suga, Takayoshi; Kakizaki, Satoru; Sohara, Naondo; Horiguchi, Norio; Uraoka, Toshio
• Is Part Of: Clinical case reports. Volume 10:Issue 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-05
• Subjects: adolescents -- chronic hepatitis C -- direct‐acting antivirals -- Japanese -- special population; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5690
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Three Japanese adolescents with chronic hepatitis C were treated by direct‐acting antivirals (DAAs). No adverse events or laboratory abnormalities were observed during and after DAA therapy, and a sustained virological response was achieved in all cases. The emotional functioning of the patients and their mothers were improved after DAA therapy. Key Clinical Message: The efficacy/safety of therapy with direct‐acting antivirals for chronic hepatitis C in Japanese adolescents were favorable and the improvement of emotional functioning of them and their mothers by viral eradication was observed in all cases.